Detail akcie Agenus online

Business Summary: Agenus Inc. is an immuno-oncology (I-O) company targeting cancer and infectious diseases with a pipeline of immunological agents. It is specialized in developing therapies to activate the body's immune system against cancer and infections. Its pipeline includes immune-modulatory antibodies, adoptive cell therapies (via MiNK Therapeutics, Inc.), and vaccine adjuvants (via SaponiQx, Inc.). Its primary focus is I-O, and its diverse pipeline is supported by its in-house capabilities, including current good manufacturing practice (cGMP) manufacturing and a clinical operations platform. Its most advanced antibody candidates are botensilimab (a multifunctional immune cell activator and human Fc-enhanced cytotoxic T-lymphocyte antigen 4 (CTLA-4) blocking antibody (AGEN1811)) and balstilimab (a programmed death receptor-1 (PD-1) blocking antibody). Its pipeline includes several classes of immunotherapies: checkpoint inhibitors, immune activators, and tumor microenvironment conditioning agents.
Financial Summary: BRIEF: For the fiscal year ended 31 December 2023, Agenus Inc revenues increased 59% to $156.3M. Net loss applicable to common stockholders increased 12% to $246M. Revenues reflect United States segment increase of 75% to $153.3M. Higher net loss reflects R & D expenses increase of 26% to $228.3M (expense), Interest expense, net - Balancing value increase of 51% to $92.9M (expense).